Related references
Note: Only part of the references are listed.A versatile high-performance LC-MS/MS assay for the quantification of voriconazole and its N-oxide metabolite in small sample volumes of multiple human matrices for biomedical applications
Josefine Schulz et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2022)
Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism
Josefine Schulz et al.
PHARMACEUTICS (2022)
Microdialysis of Drug and Drug Metabolite: a Comprehensive In Vitro Analysis for Voriconazole and Voriconazole N-oxide
Josefine Schulz et al.
PHARMACEUTICAL RESEARCH (2022)
Quantification of microdialysis related variability in humans: Clinical trial design recommendations
David Busse et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)
Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated
Elodie Gautier-Veyret et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Favorable Effects of Voriconazole Trough Concentrations Exceeding 1 μg/mL on Treatment Success and All-Cause Mortality: A Systematic Review and Meta-Analysis
Yuki Hanai et al.
JOURNAL OF FUNGI (2021)
Pharmacokinetics and phenotyping properties of the Basel phenotyping cocktail combination capsule in healthy male adults
Claudia Suenderhauf et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Mohd H. Abdul-Aziz et al.
INTENSIVE CARE MEDICINE (2020)
Emerging Issues in Antifungal Resistance
John R. Perfect et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2020)
Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium
Amir Arastehfar et al.
ANTIBIOTICS-BASEL (2020)
High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis
Claudia Kirbs et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children
A. Warris et al.
CLINICAL MICROBIOLOGY AND INFECTION (2019)
Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism
Josefine Schulz et al.
DRUG METABOLISM REVIEWS (2019)
Antifungal drugs: What brings the future?
Ruth Van Daele et al.
MEDICAL MYCOLOGY (2019)
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
A. J. Ullmann et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the Metabolites in Safety Testing Regulatory Guidance
Simone Schadt et al.
DRUG METABOLISM AND DISPOSITION (2018)
Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients
Iris K. Minichmayr et al.
CLINICAL PHARMACOKINETICS (2017)
The global problem of antifungal resistance: prevalence, mechanisms, and management
David S. Perlin et al.
LANCET INFECTIOUS DISEASES (2017)
Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections
Issam S. Hamadeh et al.
PHARMACOGENETICS AND GENOMICS (2017)
Observational Study of Associations between Voriconazole Therapeutic Drug Monitoring, Toxicity, and Outcome in Liver Transplant Patients
Zahra Hashemizadeh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Felix Bongomin et al.
JOURNAL OF FUNGI (2017)
Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics
Nicolas Hohmann et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Microdialysis as an Important Technique in Systems Pharmacology-a Historical and Methodological Review
Margareta Hammarlund-Udenaes
AAPS JOURNAL (2017)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy
B. Moriyama et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole
Nicolas Hohmann et al.
CLINICAL PHARMACOKINETICS (2016)
Utility of voriconazole therapeutic drug monitoring: a meta-analysis
Me-Linh Luong et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
A retrospective analysis of patient-specific factors on voriconazole clearance
Satoshi Dote et al.
JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES (2016)
Variability of Voriconazole Plasma Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Cytochrome P450 Polymorphisms and Comedications on Initial and Subsequent Trough Levels
Elodie Gautier-Veyret et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Saturated Metabolism of Voriconazole N-Oxidation Resulting in Non linearity of Pharmacokinetics of Voriconazole at Clinical Doses
Takahiro Yamada et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2015)
Voriconazole N-oxide and its ultraviolet B photoproduct sensitize keratinocytes to ultraviolet A
K. Ona et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Key Elements in Determining Voriconazole Protein Binding Characteristics: Comment on Determination of Plasma Unbound Fraction of Voriconazole in Patients Treated With a Prophylactic or a Curative Treatment
Kim Vanstraelen et al.
THERAPEUTIC DRUG MONITORING (2015)
Tissue Penetration of Antifungal Agents
Timothy Felton et al.
CLINICAL MICROBIOLOGY REVIEWS (2014)
Voriconazole pharmacokinetics and exposure-response relationships: Assessing the links between exposure, efficacy and toxicity
Michael J. Dolton et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
Voriconazole Metabolism, Toxicity, and the Effect of Cytochrome P450 2C19 Genotype
Dimitrios Zonios et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Protein-Binding Characteristics of Voriconazole Determined by High-Throughput Equilibrium Dialysis
Vanstraelen Kim et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
CYP2C19 Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?
Aniwaa Owusu Obeng et al.
PHARMACOTHERAPY (2014)
Pilot Investigation on Long-Term Subcutaneous Microdialysis: Proof of Principle in Humans
Franziska Simmel et al.
AAPS JOURNAL (2013)
Potential Factors for Inadequate Voriconazole Plasma Concentrations in Intensive Care Unit Patients and Patients with Hematological Malignancies
Martin Hoenigl et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
A Multistep Voriconazole-Related Phototoxic Pathway May Lead to Skin Carcinoma: Results From a French Nationwide Study
Olivier Epaulard et al.
CLINICAL INFECTIOUS DISEASES (2013)
Steady-state pharmacokinetics and metabolism of voriconazole in patients
Marcus J. P. Geist et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring
Michael J. Dolton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Hidden Killers: Human Fungal Infections
Gordon D. Brown et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Microdialysis feasibility investigations with the non-hydrophilic antifungal voriconazole for potential applications in nonclinical and clinical settings
F. Simmel et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Phototoxicity and photocarcinogenesis associated with voriconazole
O. Epaulard et al.
MEDECINE ET MALADIES INFECTIEUSES (2011)
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype
Ina Scholz et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Treatment of aspergillosis: Clinical practice guidelines of the infectious diseases society of America
Thomas J. Walsh et al.
CLINICAL INFECTIOUS DISEASES (2008)
Tissue concentrations: do we ever learn?
Johan W. Mouton et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses?
Ursula Theuretzbacher
CURRENT OPINION IN PHARMACOLOGY (2007)
In vivo efficacy and pharmacokinetics of voriconazole in an animal model of dermatophytosis
D. A. Saunte et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes
Norie Murayama et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Potent cytochrome P4502C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir
Gerd Mikus et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis
Cornelia Buerger et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Microdialysis - theoretical background and recent implementation in applied life-sciences
N Plock et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2005)
The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human
SJ Roffey et al.
DRUG METABOLISM AND DISPOSITION (2003)
Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole
R Hyland et al.
DRUG METABOLISM AND DISPOSITION (2003)
Share Paper
